Barrie Carter, Ph.D.

Dr. Carter was the Executive Vice President and Chief Scientific Officer of Targeted Genetics Corporation from 1992 until 2008. Previously, he was at the National Institutes of Health (NIH) for 22 years serving as Chief of the Laboratory of Molecular and Cellular Biology in the National Institute for Diabetes and Digestive and Kidney Diseases from 1982 to 1992. He received his B.Sc. with Honors from the University of Otago, Dunedin, New Zealand and his Ph.D. in the Biochemistry Department of the University of Otago Medical School. Dr. Carter’s long-term research interests are in the molecular biology of viruses, development of AAV vectors and gene therapy. Dr. Carter serves on the editorial boards of Human Gene Therapy and Virology from 1995-2000. Dr. Carter currently serves as a member of the Advisory Committee to the Director of NIH and is a member of the Board of Directors of the American Society for Gene Therapy.

Jane Lebkowski Ph.D.

Dr Lebkowski was recently the Chief Scientific Officer of Geron Corporation. Prior to Geron she was Vice president of Discovery Research at Rhone-Poulenc Rorer and Vice President of R&D at Applied Immune Sciences. Dr. Lebkowski holds a Ph.D. in Biochemistry from Princeton University and is an internationally recognized expert in stem cell biology and regenerative medicine. She has authored over 70 peer – reviewed papers and 12 issued US Patents.

Mark Reisman MD

Dr. Reisman is the Director of Swedish Medical Center Cardiac catheterization laboratory, Partner with Seattle Heart and Vascular Consultants, and, President of the Seattle Science Foundation. He is a Professor of Medicine at the University of Washington and co-chair of the Clinical Outcomes Assessment Program of the State of Washington. Dr. Reisman is board certified in cardiology and has been Principal Investigator for dozens of clinical trials. Dr. Reisman holds a Bachelors Degree from SUNY – Stonybrook, and a Medical Degree from the Sackler Medical School, New York, NY. He did an internship in Internal Medicine at the Robert Wood Johnson Medical Center in Brunswick NJ, a Fellowship in Cardiology at St. Lukes Medical Center in New York, NY, and, a Fellowship in Interventional Cardiology at UC San Diego Medical Center.

Warren Sherman, MD

Dr. Sherman is an Interventional Cardiologist at Columbia University Medical Center/NewYork-Presbyterian Hospital, the Director, Stem Cell Research and Regenerative Medicine at the Center for Interventional Vascular Therapy, and Associate Professor of Medicine at Columbia University College of Physicians and Surgeons. Dr. Sherman’s areas of expertise include a cell-based and other regenerative therapies for treating patients with chronic heart failure and following acute myocardial infarction. Dr. Sherman received his B.S. degree from the Massachusetts Institute of Technology, Doctor of Medicine from Upstate University of New York in Syracuse, NY and Cardiology Fellowship at Oregon Health Sciences University

Max Lyon, MBA

Mr. Lyon is a senior executive, entrepreneur, and consultant with a 25 year career in biomedical technology including pharmaceuticals, medical devices/diagnostics and healthcare IT. Major activity has been with startup and development stage companies. Mr. Lyon has been CEO/President of eight medical technology companies, four of which he co-founded, including BioControl Systems, Bainbridge Sciences (Bard Diagnostics), CG Therapeutics, Adeona Pharmaceuticals (AMEX:AEN), NexCura, Confirma, LifeSpex and FiatLux Imaging. Mr. Lyon currently has a consulting practice focused on start-up and development stage companies. In 2005, he received the Frost & Sullivan Northwest Healthcare Entrepreneur of the Year award. He holds both BA (Cornell University) and MBA degrees.